1. Reduced Annexin A3 in schizophrenia
- Author
-
Mauricio H. Serpa, Helena Passarelli Giroud Joaquim, Alana C. Costa, Leda Leme Talib, and Wagner F. Gattaz
- Subjects
Adult ,Male ,medicine.medical_specialty ,Bipolar Disorder ,Inflammation ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Western blot ,Internal medicine ,mental disorders ,Neuroplasticity ,Humans ,Medicine ,Pharmacology (medical) ,Platelet ,Bipolar disorder ,Annexin A3 ,Biological Psychiatry ,medicine.diagnostic_test ,business.industry ,General Medicine ,medicine.disease ,030227 psychiatry ,Psychiatry and Mental health ,Endocrinology ,Schizophrenia ,Apoptosis ,Female ,medicine.symptom ,business ,Biomarkers ,030217 neurology & neurosurgery - Abstract
The cellular and molecular mechanisms underlying onset and development of schizophrenia have not yet been completely elucidated, but the association of disturbed neuroplasticity and inflammation has gained particular relevance recently. These mechanisms are linked to annexins functions. ANXA3, particularly, is associated to inflammation and membrane metabolism cascades. The aim was to determine the ANXA3 levels in first-onset drug-naive psychotic patients. We investigated by western blot the protein expression of annexin A3 in platelets of first-onset, drug-naive psychotic patients (diagnoses according to DSM-IV: 28 schizophrenia, 27 bipolar disorder) as compared to 30 age- and gender-matched healthy controls. Annexin A3 level was lower in schizophrenia patients as compared to healthy controls (p
- Published
- 2019